| Not Yet Recruiting | Long-term Study to Evaluate Safety and Persistence of GF-CART01 NCT06985576 | GenomeFrontier Therapeutics TW Co., Ltd. | — |
| Not Yet Recruiting | A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance NCT07511114 | Ruijin Hospital | Phase 3 |
| Not Yet Recruiting | Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cel NCT07472621 | Henan Cancer Hospital | — |
| Not Yet Recruiting | Glofitamab Combined With CAR-T Therapy in R/R DLBCL NCT07326371 | Ruijin Hospital | Phase 2 |
| Recruiting | Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905 | ModeX Therapeutics, An OPKO Health Company | Phase 1 / Phase 2 |
| Not Yet Recruiting | Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL NCT07389356 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Recruiting | This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946 | LTZ Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymp NCT07231250 | Li Zhiming | Phase 2 |
| Recruiting | DALY II Japan/MB-CART2019.1 for DLBCL NCT07288879 | Miltenyi Biomedicine GmbH | Phase 2 |
| Recruiting | Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL NCT07255963 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Not Yet Recruiting | ImmunoMRI for Assessment of Tumor-associated Macrophages NCT07066436 | Medical University of Vienna | EARLY_Phase 1 |
| Not Yet Recruiting | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patien NCT07034508 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ NCT06846463 | Virginia Commonwealth University | Phase 2 |
| Recruiting | Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL NCT07057765 | Ain Shams University | — |
| Not Yet Recruiting | AZA Combined with R-GemOx for Elderly DLBCL Patients NCT06778902 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Recruiting | A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma NCT06736613 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265 | Verismo Therapeutics | Phase 1 |
| Completed | FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow NCT06592846 | The Lymphoma Academic Research Organisation | — |
| Recruiting | Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular S NCT06891157 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell NCT06220032 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 |
| Recruiting | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study NCT06534762 | Zhejiang Provincial People's Hospital | Phase 2 |
| Recruiting | Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict) NCT06526065 | University Medical Center Goettingen | — |
| Recruiting | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies NCT06014762 | Poseida Therapeutics, Inc. | Phase 1 |
| Recruiting | Glofitamab in Chinese Patients With R/R DLBCL NCT06481826 | Peking Union Medical College Hospital | — |
| Recruiting | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients NCT06287398 | Australasian Leukaemia and Lymphoma Group | Phase 2 |
| Recruiting | Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Mo NCT06299553 | Incyte Biosciences Italy S.r.l | — |
| Recruiting | Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL NCT06151080 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | AZA Combined With RCHOP in P53-mutated DLBCL. NCT06158399 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | Real-World Study of DLBCL With Different Genetic Subtypes NCT06026488 | Ruijin Hospital | — |
| Recruiting | Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta NCT05950802 | University Health Network, Toronto | Phase 1 |
| Recruiting | Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers NCT05940272 | Memorial Sloan Kettering Cancer Center | N/A |
| Active Not Recruiting | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma NCT05621096 | University of Nebraska | Phase 1 |
| Recruiting | Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL NCT05641428 | University Medical Center Groningen | Phase 2 |
| Unknown | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies NCT05487651 | Athenex, Inc. | Phase 1 |
| Unknown | Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell T NCT06026644 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | CAR-T Followed by Bispecific Antibodies NCT04889716 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Active Not Recruiting | An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcom NCT06734078 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |